Novavax Inc NVAX.O said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates the development of shots to protect against the BA.4 and BA.5 subvariants.
The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.
- Childhood Cancer Canada calls for $15M from feds as demand rises
- ‘E-dirt bikes are not toys’: E.R. doc fears more injuries after 2 kids hit in Edmonton
- N.S. women’s health advocates question progress on promised menopause clinic
- More than 100 Saskatchewan pharmacies to offer strep throat, ear infection care
Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.
The company’s vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)
Comments
Want to discuss? Please read our Commenting Policy first.